drugset
drugset / Trial / NCT03778619

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

NCT03778619 ↗

Phase 1/2 Unknown 9 enrolled GC Cell Corporation
NaSingle-groupOpen-labelTreatment

Summary

To determine the efficacy and safety of combined therapy of determined MG4101 dose and Rituximab.

Timeline

Start
2018-11-28
Primary completion
2020-04-20
Completion
2020-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MG4101 Cell therapy 1e+07 cells/kg Intravenous
Subject MG4101 Cell therapy 3e+07 cells/kg Intravenous
Subject MG4101 Cell therapy 9e+07 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified 250 mg/m2 Intravenous
Background Fludarabine Small molecule 20 mg/m2 Intravenous
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background aldesleukin Protein / enzyme biologic 1e+06 unknown Subcutaneous

Indications

non-Hodgkin lymphoma